Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Marker Therapeutics (MRKR) over the last 7 years, with Q3 2025 value amounting to $1.7 million.

  • Marker Therapeutics' Receivables - Other rose 12368.76% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 12368.76%. This contributed to the annual value of $2.3 million for FY2024, which is 12831.96% up from last year.
  • Latest data reveals that Marker Therapeutics reported Receivables - Other of $1.7 million as of Q3 2025, which was up 12368.76% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Receivables - Other peaked at $2.5 million during Q2 2024, and registered a low of $237.0 during Q4 2021.
  • For the 5-year period, Marker Therapeutics' Receivables - Other averaged around $1.2 million, with its median value being $1.1 million (2023).
  • Per our database at Business Quant, Marker Therapeutics' Receivables - Other plummeted by 9997.63% in 2021 and then soared by 101340379.75% in 2022.
  • Marker Therapeutics' Receivables - Other (Quarter) stood at $237.0 in 2021, then soared by 1013403.8% to $2.4 million in 2022, then tumbled by 57.21% to $1.0 million in 2023, then skyrocketed by 128.32% to $2.3 million in 2024, then dropped by 29.04% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.7 million for Q2 2025, and $2.5 million during Q1 2025.